Monday, December 15, 2008

Abbott Receives FDA Approval for Trilplix (fenofibric acid), First and Fibrate Indicated for Use in Combination With Statin for Cholesterol Management

December 15, 2008 -- Today, the U.S. FDA approved Abbott's TRILIPIX (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with lipid problems. TRILIPIX is the first and only fibrate to be approved for use in combination with a statin. In certain patients, treatment guidelines recommend the combination of a fibrate with a statin to further improve lipid levels. TRILIPIX has not been shown to prevent heart disease or heart attack.

The details can be read here.

No comments: